Fluticasone Propionate side effects: what 128,934 FDA adverse event reports show
Drug class
Inhaled corticosteroid (ics)
Brand names
Flovent Diskus
Who reports
128,934 reports · 52% serious · 6,697 with death outcome · 66% female
Used for
FLOVENT DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. FLOVENT DISKUS is an inhaled corticosteroid (ICS) indicated for: • Maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older.
What it is
Fluticasone propionate is a trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.
Boxed warning
None in the current label
Causality screen of the 40 strongest signals
What the badges mean
- Labeled adverse reaction The exact term appears in the label's warnings or adverse-reactions sections: a known, expected effect. The FAERS signal confirms the label rather than discovering anything.
- Labeled (related wording) The label describes this effect under different wording (e.g. 'neutropenia' for 'neutrophil count decreased'). Treated as known.
- Reporting / coding artifact An administrative, monitoring or exposure term (product issue, off-label use, 'test normal', overdose...). Not a biological reaction; a high PRR here reflects how reports are coded.
- Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
Strongest disproportionality signals
Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Vaginal flatulence | 158 | 174.8 139.5–219.1ROR 175.1 · calibrated p 2e-9 ✓ | 83.1 EB05 72.8 · IC025 +5.8 3/3 methods agree | Not in label — unassessed | serious n=158 · ♀ 100% (drug 66%) · 100% clinician | no trial arm names this drug |
| Appendicolith | 128 | 82.6 66.7–102.2ROR 82.7 · calibrated p 6e-7 ✓ | 54.3 EB05 46.9 · IC025 +5.2 3/3 methods agree | Not in label — unassessed | serious n=128 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Drug therapy | 99 | 72.7 57.3–92.2ROR 72.8 · calibrated p 2e-6 ✓ | 49.8 EB05 42.1 · IC025 +5.0 3/3 methods agree | Reporting / coding artifact | serious n=99 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Analgesic therapy | 92 | 69.5 54.4–88.8ROR 69.5 · calibrated p 2e-6 ✓ | 48.2 EB05 40.5 · IC025 +4.9 3/3 methods agree | Reporting / coding artifact | serious n=92 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Adrenal suppression | 156 | 36.7 30.9–43.7ROR 36.8 · calibrated p 1e-4 ✓ | 29.9 EB05 26.2 · IC025 +4.5 3/3 methods agree | Labeled adverse reaction exact term | serious n=155 · ♀ 45% (drug 66%) · 100% clinician | no trial arm names this drug |
| Mite allergy | 110 | 33.7 27.4–41.4ROR 33.7 · calibrated p 2e-4 ✓ | 27.9 EB05 23.8 · IC025 +4.3 3/3 methods agree | Not in label — unassessed | serious n=107 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Pulmonary vasculitis | 82 | 29.7 23.5–37.6ROR 29.7 · calibrated p 3e-4 ✓ | 25.1 EB05 20.8 · IC025 +4.1 3/3 methods agree | Labeled (related wording) related wording | serious n=82 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Overlap syndrome | 96 | 26.1 21.1–32.4ROR 26.2 · calibrated p 6e-4 ✓ | 22.5 EB05 19.0 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=96 · ♀ 100% (drug 66%) · 100% clinician | no trial arm names this drug |
| Chronic sinusitis | 500 | 24.9 22.7–27.4ROR 25.0 · calibrated p 7e-4 ✓ | 21.7 EB05 20.1 · IC025 +4.3 3/3 methods agree | Labeled (related wording) related wording | serious n=459 | no trial arm names this drug |
| Female genital tract fistula | 221 | 23.8 20.7–27.4ROR 23.9 · calibrated p 9e-4 ✓ | 20.8 EB05 18.6 · IC025 +4.1 3/3 methods agree | Not in label — unassessed | serious n=221 · ♀ 100% (drug 66%) · 100% clinician | no trial arm names this drug |
| Mycotic allergy | 105 | 23.0 18.8–28.2ROR 23.0 · calibrated p 0.001 ✓ | 20.2 EB05 17.1 · IC025 +3.9 3/3 methods agree | Not in label — unassessed | serious n=94 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Eosinophilic granulomatosis with polyangiitis | 242 | 22.0 19.3–25.2ROR 22.1 · calibrated p 0.001 ✓ | 19.4 EB05 17.5 · IC025 +4.0 3/3 methods agree | Not in label — unassessed | serious n=241 · ♀ 0% (drug 66%) | no trial arm names this drug |
| Chronic kidney disease-mineral and bone disorder | 125 | 21.3 17.6–25.6ROR 21.3 · calibrated p 0.002 ✓ | 18.8 EB05 16.2 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=125 | no trial arm names this drug |
| Obstructive sleep apnoea syndrome | 151 | 19.6 16.6–23.2ROR 19.6 · calibrated p 0.002 ✓ | 17.5 EB05 15.3 · IC025 +3.8 3/3 methods agree | Not in label — unassessed | serious n=148 | no trial arm names this drug |
| Dust allergy | 104 | 19.5 15.9–24.0ROR 19.6 · calibrated p 0.002 ✓ | 17.5 EB05 14.8 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=95 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Nasal oedema | 187 | 18.8 16.2–21.9ROR 18.8 · calibrated p 0.003 ✓ | 16.9 EB05 15.0 · IC025 +3.8 3/3 methods agree | Labeled (related wording) related wording | serious n=128 · ♀ 100% (drug 66%) | no trial arm names this drug |
| Infusion site discharge | 170 | 17.8 15.2–20.9ROR 17.9 · calibrated p 0.003 ✓ | 16.1 EB05 14.2 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=122 · 100% consumer | no trial arm names this drug |
| Nasal discomfort | 776 | 17.4 16.2–18.8ROR 17.5 · calibrated p 0.004 ✓ | 15.8 EB05 14.9 · IC025 +3.9 3/3 methods agree | Labeled (related wording) related wording | serious n=133 · 88% consumer | no trial arm names this drug |
| Respiratory symptom | 259 | 16.5 14.5–18.7ROR 16.5 · calibrated p 0.005 ✓ | 15.0 EB05 13.5 · IC025 +3.7 3/3 methods agree | Labeled (related wording) related wording | serious n=247 · ♀ 35% (drug 66%) | no trial arm names this drug |
| Cystic fibrosis respiratory infection suppression | 82 | 16.2 12.9–20.3ROR 16.2 · calibrated p 0.006 ✓ | 14.7 EB05 12.2 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious n=82 · ♀ 0% (drug 66%) · 100% consumer | no trial arm names this drug |
| Nephrogenic anaemia | 415 | 15.7 14.2–17.4ROR 15.8 · calibrated p 0.006 ✓ | 14.4 EB05 13.3 · IC025 +3.7 3/3 methods agree | Not in label — unassessed | serious n=415 | no trial arm names this drug |
| Temperature regulation disorder | 193 | 15.7 13.5–18.2ROR 15.7 · calibrated p 0.006 ✓ | 14.3 EB05 12.7 · IC025 +3.6 3/3 methods agree | Not in label — unassessed | serious n=192 · ♀ 100% (drug 66%) · 100% clinician | no trial arm names this drug |
| Infective pulmonary exacerbation of cystic fibrosis | 475 | 15.3 14.0–16.8ROR 15.4 · calibrated p 0.006 ✓ | 14.1 EB05 13.0 · IC025 +3.6 3/3 methods agree | Labeled (related wording) related wording | serious n=429 | no trial arm names this drug |
| Hyperparathyroidism secondary | 216 | 15.1 13.1–17.3ROR 15.1 · calibrated p 0.007 ✓ | 13.8 EB05 12.3 · IC025 +3.5 3/3 methods agree | Not in label — unassessed | serious n=215 | no trial arm names this drug |
| Conjunctivitis allergic | 119 | 14.3 11.9–17.3ROR 14.3 · calibrated p 0.009 ✓ | 13.1 EB05 11.2 · IC025 +3.3 3/3 methods agree | Labeled (related wording) related wording | serious n=108 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Nasal inflammation | 85 | 14.2 11.3–17.7ROR 14.2 · calibrated p 0.010 ✓ | 13.0 EB05 10.8 · IC025 +3.3 3/3 methods agree | Labeled (related wording) related wording | 100% consumer | no trial arm names this drug |
| Radiculopathy | 210 | 14.0 12.1–16.1ROR 14.0 · calibrated p 0.010 ✓ | 12.9 EB05 11.5 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=207 · ♀ 100% (drug 66%) | no trial arm names this drug |
| Infusion site reaction | 227 | 13.7 12.0–15.7ROR 13.7 · calibrated p 0.010 ✓ | 12.6 EB05 11.3 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | serious n=198 · ♀ 100% (drug 66%) | no trial arm names this drug |
| Rhinalgia | 211 | 13.5 11.8–15.6ROR 13.5 · calibrated p 0.011 ✓ | 12.5 EB05 11.1 · IC025 +3.4 3/3 methods agree | Not in label — unassessed | 100% consumer | no trial arm names this drug |
| Nasal ulcer | 119 | 13.0 10.8–15.6ROR 13.0 · calibrated p 0.013 ✓ | 12.0 EB05 10.2 · IC025 +3.2 3/3 methods agree | Labeled (related wording) related wording | ♀ 100% (drug 66%) · 100% consumer | no trial arm names this drug |
| Sputum increased | 154 | 12.7 10.8–15.0ROR 12.7 · calibrated p 0.014 ✓ | 11.7 EB05 10.2 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=129 | no trial arm names this drug |
| Nasal polyps | 351 | 12.7 11.4–14.1ROR 12.7 · calibrated p 0.014 ✓ | 11.8 EB05 10.8 · IC025 +3.4 3/3 methods agree | Labeled (related wording) related wording | serious n=241 | no trial arm names this drug |
| Neuritis | 104 | 11.7 9.6–14.3ROR 11.7 · calibrated p 0.019 ✓ | 10.8 EB05 9.1 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=103 · ♀ 0% (drug 66%) · 100% clinician | no trial arm names this drug |
| Facet joint syndrome | 211 | 11.6 10.1–13.3ROR 11.6 · calibrated p 0.019 ✓ | 10.8 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=211 · ♀ 100% (drug 66%) · 100% clinician | no trial arm names this drug |
| Rebound acid hypersecretion | 204 | 11.5 10.0–13.3ROR 11.5 · calibrated p 0.020 ✓ | 10.7 EB05 9.5 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=204 | no trial arm names this drug |
| Product package associated injury | 147 | 11.5 9.7–13.6ROR 11.5 · calibrated p 0.021 ✓ | 10.7 EB05 9.3 · IC025 +3.1 3/3 methods agree | Reporting / coding artifact | 100% consumer | no trial arm names this drug |
| Acute sinusitis | 113 | 11.4 9.4–13.7ROR 11.4 · calibrated p 0.022 ✓ | 10.5 EB05 8.9 · IC025 +3.0 3/3 methods agree | Labeled (related wording) related wording | serious n=91 · ♀ 100% (drug 66%) | no trial arm names this drug |
| Product delivery mechanism issue | 317 | 11.3 10.1–12.6ROR 11.3 · calibrated p 0.021 ✓ | 10.5 EB05 9.6 · IC025 +3.2 3/3 methods agree | Reporting / coding artifact | 86% consumer | no trial arm names this drug |
| Infusion site haemorrhage | 209 | 11.1 9.7–12.8ROR 11.2 · calibrated p 0.023 ✓ | 10.4 EB05 9.2 · IC025 +3.1 3/3 methods agree | Not in label — unassessed | serious n=123 · 74% consumer | no trial arm names this drug |
| Nasal dryness | 403 | 11.1 10.0–12.3ROR 11.1 · calibrated p 0.022 ✓ | 10.4 EB05 9.6 · IC025 +3.2 3/3 methods agree | Not in label — unassessed | serious n=81 · 87% consumer | no trial arm names this drug |
Clinical concept groups
MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.
| Concept | Reports | PRR 95% CI | Reading |
|---|---|---|---|
| Serious infection | 9,635 | 2.02.0–2.1 | signal |
| Depression | 3,396 | 2.01.9–2.0 | raised |
| Tendon disorder | 406 | 1.71.6–1.9 | raised |
| Fall / fracture | 3,827 | 1.61.6–1.7 | raised |
| Hyponatraemia | 807 | 1.61.5–1.8 | raised |
| Venous thromboembolism | 2,110 | 1.61.5–1.7 | raised |
| Kidney injury | 4,144 | 1.51.4–1.5 | raised |
| Arrhythmia / qt | 1,698 | 1.41.4–1.5 | raised |
| Anaphylaxis / angioedema | 1,050 | 1.41.3–1.4 | raised |
| Gi bleeding | 1,514 | 1.31.3–1.4 | raised |
| Opportunistic infection | 1,122 | 1.31.3–1.4 | raised |
| Heart failure | 1,409 | 1.31.2–1.4 | raised |
| Anaemia | 2,321 | 1.31.2–1.3 | raised |
| Interstitial lung disease | 720 | 1.21.1–1.3 | raised |
| Hyperglycaemia / diabetes | 2,373 | 1.11.1–1.2 | raised |
| Liver injury | 1,893 | 1.01.0–1.1 | no difference |
Trial evidence (ClinicalTrials.gov)
Most frequently reported reactions
By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.
| Reaction | Reports | PRR 95% CI · ROR · χ²/p | EBGM EB05 · IC025 | Label screen | Serious-only & strata | Trial cross-check |
|---|---|---|---|---|---|---|
| Drug ineffective (drug did not work) | 10,324 | 1.3 1.3–1.3ROR 1.3 · calibrated p 0.508 | 1.3 EB05 1.3 · IC025 +0.3 | Reporting / coding artifact | age-adj. PRR 1.4 · serious PRR 1.4 | no trial arm names this drug |
| Dyspnoea (shortness of breath) | 8,658 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.764 | 2.5 EB05 2.4 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.5 · serious PRR 2.8 | no trial arm names this drug |
| Fatigue (tiredness) | 8,572 | 1.8 1.8–1.8ROR 1.9 · calibrated p 0.865 | 1.8 EB05 1.8 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.2 | no trial arm names this drug |
| Headache | 8,350 | 2.2 2.1–2.2ROR 2.3 · calibrated p 0.920 | 2.2 EB05 2.1 · IC025 +1.1 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.6 | no trial arm names this drug |
| Nausea | 7,451 | 1.5 1.5–1.6ROR 1.6 · calibrated p 0.689 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 2.0 | no trial arm names this drug |
| Pain | 6,458 | 1.7 1.7–1.8ROR 1.8 · calibrated p 0.800 | 1.7 EB05 1.7 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 2.1 · serious PRR 2.1 | no trial arm names this drug |
| Off label use (used outside approved label) | 6,372 | 1.2 1.2–1.2ROR 1.2 · calibrated p 0.443 | 1.2 EB05 1.2 · IC025 +0.2 | Reporting / coding artifact | age-adj. PRR 1.2 · serious PRR 1.4 | no trial arm names this drug |
| Diarrhoea (diarrhea) | 6,366 | 1.6 1.6–1.7ROR 1.6 · calibrated p 0.736 | 1.6 EB05 1.6 · IC025 +0.6 | Not in label — unassessed | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Cough | 5,738 | 3.4 3.3–3.5ROR 3.5 · calibrated p 0.486 | 3.3 EB05 3.3 · IC025 +1.7 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 3.2 · serious PRR 3.8 | no trial arm names this drug |
| Dizziness | 5,412 | 1.8 1.7–1.8ROR 1.8 · calibrated p 0.835 | 1.8 EB05 1.7 · IC025 +0.8 | Labeled adverse reaction exact term | age-adj. PRR 1.8 · serious PRR 2.1 | no trial arm names this drug |
| Pneumonia (lung infection) | 5,011 | 2.5 2.5–2.6ROR 2.6 · calibrated p 0.769 | 2.5 EB05 2.5 · IC025 +1.3 3/3 methods agree | Labeled adverse reaction exact term | age-adj. PRR 2.6 · serious PRR 2.9 | no trial arm names this drug |
| Asthma | 4,762 | 7.2 7.0–7.4ROR 7.4 · calibrated p 0.084 | 6.9 EB05 6.7 · IC025 +2.7 3/3 methods agree | Likely indication confounding term in indications; also in warnings | age-adj. PRR 8.0 · serious PRR 8.3 | no trial arm names this drug |
| Vomiting | 4,398 | 1.5 1.5–1.6ROR 1.5 · calibrated p 0.673 | 1.5 EB05 1.5 · IC025 +0.6 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
| Arthralgia (joint pain) | 4,232 | 1.7 1.6–1.7ROR 1.7 · calibrated p 0.762 | 1.7 EB05 1.6 · IC025 +0.7 | Labeled adverse reaction exact term | age-adj. PRR 1.7 · serious PRR 2.1 | no trial arm names this drug |
| Rash | 4,014 | 1.5 1.5–1.6ROR 1.5 · calibrated p 0.658 | 1.5 EB05 1.5 · IC025 +0.5 | Labeled adverse reaction exact term | age-adj. PRR 1.6 · serious PRR 1.9 | no trial arm names this drug |
Unlabeled candidate signals
These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.
- Vaginal flatulence — n=158, PRR 174.8
- Appendicolith — n=128, PRR 82.6
- Mite allergy — n=110, PRR 33.7
- Overlap syndrome — n=96, PRR 26.1
- Female genital tract fistula — n=221, PRR 23.8
- Mycotic allergy — n=105, PRR 23.0
- Eosinophilic granulomatosis with polyangiitis — n=242, PRR 22.0
- Chronic kidney disease-mineral and bone disorder — n=125, PRR 21.3
- Obstructive sleep apnoea syndrome — n=151, PRR 19.6
- Dust allergy — n=104, PRR 19.5
Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.
Common questions
What are the most reported side effects of Fluticasone Propionate?
In FDA FAERS, the most frequently co-reported reaction terms for Fluticasone Propionate are dyspnoea, fatigue, headache, nausea, pain, diarrhoea. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.
Does Fluticasone Propionate have an FDA boxed warning?
No. The FDA label retrieved for Fluticasone Propionate has no boxed warning; see the label's Warnings and Precautions for the recognised risks.
Do FAERS signals prove that Fluticasone Propionate causes these side effects?
No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.
Sources & methods
- FDA label via openFDA (set ID 038e6c40-9421-40ef-874b-8f4d7110a74a, effective 20240111; matched on
openfda.generic_name.exact:"FLUTICASONE PROPIONATE" AND openfda.product_type:"HUMAN PRESCRIPTION DRUG") - PubChem CID 444036 description (ChEBI)
- Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
- FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA
count=aggregation, fieldpatient.drug.openfda.generic_name.exact, 1,184 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction - Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
- Seriousness and sex counts from openFDA
count=serious,patient.patientsex,seriousnessdeath - ClinicalTrials.gov API v2 (query
FLUTICASONE PROPIONATE, results-bearing studies sorted by enrollment)
Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.